MonoSol Rx Appoints Santo J. Costa as new board member

MonoSol Rx, the developer of PharmFilm drug delivery technology, recently appointed Santo “Sandy” Costa to its board of directors.

Costa, who earned a B.S. in pharmacy and his J.D. from St. John’s University, brings with him over 40 years of experience in both the pharmaceutical and health-care industries as well a history of heading his own legal practice. Costa is Of Counsel at the law firm Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan in Raleigh, North Carolina .and currently sits on the board of Cytokinetics Inc. and is chairman of Metabon Inc.

“I am quite pleased to have the opportunity to serve on the MonoSol Rx Board of Directors,” Costa said “MonoSol Rx is a unique and innovative company that has repeatedly demonstrated the versatility of its lead product, PharmFilm. In my time on the board of directors, it is my goal to see the company expand even further with their partnership, research, and development initiatives.”

Coasta gained years of executive level experience while serving as president, COO, and vice chairman of Quintiles Transnational Corp. and as SVP-administration, general counsel and director of Glaxo Inc.

“We are grateful to have Sandy as the newest member of our board. His decades of successful executive leadership in the pharmaceutical industry make him an obvious choice for us,” CEO of MonoSol Rx Keith Kendall said. “We are confident Mr. Costa will help MonoSol Rx continue to grow and influence the specialty pharmaceutical market.”